Loading…
ImageneBio, Inc. is projected to rise to $5.76 by 2027, a +3% move from its current price of $5.59. IMA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/25/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 26 | $5.42 | $5.59 | $5.77 | -0.02% |
| Jul 27 | $5.34 | $5.59 | $5.84 | -0.04% |
| Jul 28 | $5.29 | $5.59 | $5.90 | -0.06% |
| Jul 29 | $5.24 | $5.59 | $5.95 | -0.08% |
| Jul 30 | $5.20 | $5.58 | $5.99 | -0.10% |
| Jul 31 | $5.17 | $5.58 | $6.03 | -0.12% |
| Aug 1 | $5.14 | $5.58 | $6.07 | -0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.14 | $5.58 | $6.07 | -0.14% |
| Week 2 | $4.95 | $5.57 | $6.27 | -0.29% |
| Week 3 | $4.82 | $5.57 | $6.43 | -0.43% |
| Week 4 | $4.70 | $5.56 | $6.57 | -0.57% |
| Week 5 | $4.61 | $5.55 | $6.69 | -0.71% |
| Week 6 | $4.52 | $5.54 | $6.80 | -0.85% |
| Week 7 | $4.44 | $5.53 | $6.90 | -1.00% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate IMG-007 is a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio is headquartered in San Diego, California.
ImageneBio, Inc. (IMA) is a healthcare company with a current price of $5.57 per share and a market capitalization of $62.82M. It ranks 4365. The lead product candidate IMG-007 is a non-depleting anti-OX40 monoclonal antibody that binds to the OX40 receptor on activated T cells to block receptor binding to OX40 ligand and is in Phase 1b/2a clinical trial.
Forecasts show a gradual rise in average price by year with increasingly bullish momentum beginning in 2031 and beyond, as summarized by year-by-year averages and ROIs.
A major floor 18.6% below — a decisive break under it would weaken the trend.
The nearest floor, 3.8% below — buyers have tended to step in here.
The nearest ceiling, 9.3% above — a clean break opens room to run.
A major ceiling 14.8% above — clearing it would confirm fresh momentum.
Key IMA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.73 | Sell | $5.76 | Sell |
| MA 10 | $5.82 | Sell | $5.80 | Sell |
| MA 20 | $5.88 | Sell | $5.82 | Sell |
| MA 50 | $5.76 | Sell | $5.81 | Sell |
| MA 100 | $5.71 | Sell | $6.02 | Sell |
| MA 200 | $6.44 | Sell | $7.29 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.16 | Neutral |
| Stoch RSI (14) | 33.23 | Neutral |
| CCI (20) | -133.44 | Sell |
| Williams %R (14) | -73.97 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -8.24 | Sell |
| Bollinger %B (20,2) | 0.11 | Neutral |
| Stochastic %K (14) | 26.03 | Neutral |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 40.58 | Neutral |
| Momentum (10) | -0.33 | Sell |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 5.84 | Sell |
| ADX (14) | 11.11 | Neutral |
| ATR (14) | 0.16 | Info |
The near-term technical picture is BEARISH with RSI14 at 40. The price is currently near the SMA50 of $5.76 and below the SMA200 at $6.44, with a defined support at $5.38 and resistance at $6.11. The 30-day range runs from $4.53 to $6.86, illustrating notable short-term volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.55 | $5.59 | $7.15 | 0% | Neutral | |
| $4.53 | $5.76 | $7.80 | +3% | Neutral | |
| $4.24 | $5.57 | $7.86 | 0% | Neutral | |
| $4.31 | $5.83 | $8.50 | +4% | Neutral | |
| $4.46 | $6.18 | $9.26 | +11% | Neutral | |
| $5.19 | $7.35 | $11.27 | +31% | Bullish | |
| $5.82 | $8.41 | $13.18 | +50% | Bullish | |
| $5.78 | $8.52 | $13.62 | +52% | Bullish | |
| $6.16 | $9.25 | $15.05 | +66% | Bullish | |
| $5.85 | $8.95 | $14.79 | +60% | Bullish | |
| $8.31 | $13.79 | $24.40 | +147% | Bullish | |
| $11.08 | $21.19 | $41.41 | +279% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.55 | $5.59 | $6.64 | +0.00% |
| August 2026 | $4.72 | $5.57 | $6.75 | -0.38% |
| September 2026 | $4.61 | $5.49 | $6.74 | -1.47% |
| October 2026 | $4.73 | $5.67 | $7.05 | +3.35% |
| November 2026 | $4.80 | $5.80 | $7.28 | +2.28% |
| December 2026 | $4.65 | $5.65 | $7.15 | -2.65% |
Click any year to see its month-by-month IMA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, IMA is projected to trade between $4.55 and $7.15, averaging $5.59 — a potential gain of 0% from today's $5.59. Price action looks broadly range-bound.
ImageneBio, Inc.'s 2027 outlook centres on $5.76, within a $4.53 to $7.80 range. That is up +3% on the projected 2026 average. That marks a +3% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, IMA could reach as high as $7.86, with a base case around $5.57 and support toward $4.24 — roughly 0% from $5.59. Price action looks broadly range-bound.
Expect IMA to range from $4.31 to $8.50 through 2029. The $5.83 average target implies a +4% move from current prices. That is up +5% on the projected 2028 average. A consolidation phase looks the most probable path here.
The IMA price prediction for 2030 points to an average of $6.18 (low $4.46, high $9.26) — a potential gain of +11% on today's $5.59. Price action looks broadly range-bound.
In 2031, IMA is projected to trade between $5.19 and $11.27, averaging $7.35 — a potential gain of +31% from today's $5.59. That is up +19% on the projected 2030 average. Buyers look set to stay in control over this stretch.
ImageneBio, Inc.'s 2032 outlook centres on $8.41, within a $5.82 to $13.18 range. That is up +14% on the projected 2031 average. That marks a +50% change versus current levels. Momentum favours further upside here.
By 2033, IMA could reach as high as $13.62, with a base case around $8.52 and support toward $5.78 — roughly +52% from $5.59. Buyers look set to stay in control over this stretch.
Expect IMA to range from $6.16 to $15.05 through 2034. The $9.25 average target implies a +66% move from current prices. That is up +9% on the projected 2033 average. Momentum favours further upside here.
The IMA price prediction for 2035 points to an average of $8.95 (low $5.85, high $14.79) — a potential gain of +60% on today's $5.59. Buyers look set to stay in control over this stretch.
In 2040, IMA is projected to trade between $8.31 and $24.40, averaging $13.79 — a potential gain of +147% from today's $5.59. That is up +54% on the projected 2035 average. Momentum favours further upside here.
ImageneBio, Inc.'s 2050 outlook centres on $21.19, within a $11.08 to $41.41 range. That is up +54% on the projected 2040 average. That marks a +279% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in IMA today (≈ 178.890877 IMA) could be worth
$3,791.44
+$2,791.44 (+279%) by 2050 · US Dollar
Based on the average projected IMA price of $21.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMAwould be worth at today's price.
$1,000 invested in IMA on Jul 23, 2025 (≈ 60.386475 IMA) would be worth
$337.56
-$662.44 (-66.2%) today · 0.34× · US Dollar
Based on a IMA entry price of $16.56 vs. today's $5.59.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.45 | $1,025.69 | +2.6% |
| 1 month ago | $6.01 | $930.12 | -7.0% |
| 3 months ago | $5.71 | $978.98 | -2.1% |
| 6 months ago | $7.22 | $774.24 | -22.6% |
| 1 year ago | $16.56 | $337.56 | -66.2% |
| All time (5.0y) ago | $137.88 | $40.54 | -95.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMA forecast.
Our base-case forecast reaches $11.00 around 2040.
Implied market cap at $11.00: $124.07M
The multi-year forecast shows a shift from NEUTRAL to BULLISH from 2031 onward, with the average price rising from $7.32 in 2031 to $21.10 by 2050 and a corresponding rise in ROI from 31.4% (2031) to 278.8% (2050). Key milestones include 2030 avg $6.17 with ROI 10.7%, 2032 avg $8.38, 2033 avg $8.51, 2034 avg $9.22, 2035 avg $8.90, 2040 avg $13.73, and 2050 avg $21.10. Sentiment is NEUTRAL through 2030 and BULLISH from 2031 onward, reflecting an assumed longer-term upside despite near-term volatility.
Tap a question to reveal the answer.
2030 forecast: min $4.45, avg $6.17, max $9.24; ROI 10.7%; sentiment NEUTRAL.
Forecasts show increasing average prices from 2031 onward (2031 avg $7.32; 2032 avg $8.38; 2033 avg $8.51; 2034 avg $9.22; 2035 avg $8.90) with ROI rising to 31.4% in 2031 and 278.8% by 2050, and sentiment turning BULLISH after 2031. These are estimates, not guarantees.
Yes, the 2031 maximum is $11.23, while the 2030 maximum is $9.24. The 2031 maximum indicates it could exceed $10 under the forecasted path.
Current price is $5.57 and market cap is $62.82M.
The 30-day range is $4.53 to $6.86 and the annualized volatility is 60%.
ImageneBio, Inc. Community Discussion
0Share your ImageneBio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.